Aggressive T-cell lymphoma, a rare form of blood cancer, continues to pose significant challenges for clinicians due to its low five-year survival rate and frequent relapses after initial therapy. Researchers from the Massachusetts Institute of Technology (MIT), in collaboration with the PETAL consortium at Massachusetts General Hospital, have identified a prognostic marker that may help doctors identify high-risk patients earlier and tailor treatment strategies accordingly.
The study found that patients who relapse within 12 months of their initial therapy—marked by what researchers call TTR12—face much lower chances of survival. For these individuals, targeted therapies could potentially offer better outcomes than traditional chemotherapy.
Using data from thousands of patients worldwide, the research team determined that this finding holds true across various patient subgroups, regardless of the type of initial therapy or scores on commonly used prognostic indices. The analysis relied on a causal inference framework known as Synthetic Survival Controls (SSC), developed during MIT graduate student Jessy (Xinyi) Han's thesis work. This method allows researchers to estimate how outcomes might change under different interventions despite inconsistencies and biases in available data.
The identification of novel risk groups could assist clinicians in selecting therapies aimed at improving overall survival rates. The results may also inform criteria for clinical trial participation.
According to Han: "No experiment can answer that question because we are asking about two outcomes for the same patient. We have to borrow information from other patients to estimate, counterfactually, what a patient's survival outcome would have been."
Han added: "This tells us that early relapse is a very important prognosis. This acts as a signal to clinicians so they can think about tailored therapies for these patients that can overcome resistance in second-line or third-line."
Senior author Shah commented: "Based on our work, there is already a risk calculation tool being used by clinicians. With more information, we can make it a richer tool that can provide more prognostic details."
The research was published in the journal Blood and included contributions from co-authors such as Mark N. Sorial from Dana-Farber Cancer Institute and Salvia Jain from Massachusetts General Hospital Cancer Center and Harvard Medical School.
Beyond oncology applications, the SSC framework has been applied by MIT researchers in areas like criminal justice and insurance decision-making. In one recent study presented at an academic conference, they identified differences in recidivism rates among prisoners based on race starting seven months after release—a pattern possibly linked to varying access to long-term support services.
Han noted: "Partnering with domain experts is crucial because we want to demonstrate that our methods are of value in the real world. We hope these tools can be used to positively impact individuals across society."
Funding for this research came from several organizations including Daiichi Sankyo, Secure Bio Inc., Acrotech Biopharma, Kyowa Kirin, Center for Lymphoma Research, National Cancer Institute, Massachusetts General Hospital, Reid Fund for Lymphoma Research, American Cancer Society, and Scarlet Foundation.
